O
OS Therapies Incorporated (OSTX)
ASE – Real vaqt narxi. Valyuta: USD
1.41
+0.04 (2.92%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.41
-0.00 (-0.01%)
Bozordan keyin: Mar 27, 2026, 7:53 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
ASE – Real vaqt narxi. Valyuta: USD
1.41
+0.04 (2.92%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
1.41
-0.00 (-0.01%)
Bozordan keyin: Mar 27, 2026, 7:53 PM EDT
OS Therapies Incorporated, klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda osteosarkoma va boshqa qattiq o'smalar uchun davolash usullarini aniqlash, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning quvur liniyasi osteosarkoma bemorlari uchun tayyor immünoterapiya bo'lgan OST-HER2; va sozlanishi mumkin bo'lgan pH sezgir silikon linkerdan iborat plug-and-play platformasiga ega bo'lgan antitel-dorivor konjugat (ADC) silikon dioksid linker texnologiyasi bo'lgan OST-tunable drug conjugate (OST-tADC)ni o'z ichiga oladi. OS Therapies Incorporated 2018 yilda tashkil etilgan va Grasonville, Merilendda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Robert G. Petit II, Ph.D. | Chief Medical Officer & Chief Scientific Officer |
| Mr. Christopher P. Acevedo | Chief Financial Officer |
| Mr. Gerald E. Commissiong | Chief Business Officer |
| Mr. Jack Doll | Chief of Staff |
| Mr. Paul A. Romness M.P.H. | Founder, Chairman, President & CEO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-06 | 8-K | ea0280014-8k_ostherapies.htm |
| 2026-01-20 | D | |
| 2026-01-12 | 8-K | ea0272516-8k_ostherap.htm |
| 2025-11-14 | 10-Q | ea0265250-10q_ostherap.htm |
| 2025-10-31 | S-8 | ea0262504-s8_osthera.htm |
| 2025-10-21 | 8-K | ea0261939-8k_ostherap.htm |
| 2025-10-17 | 8-K | ea0261257-8k_ostherapies.htm |
| 2025-09-30 | 8-K | ea0259321-8k_ostherap.htm |
| 2025-09-10 | D | |
| 2025-09-02 | 8-K | ea0255568-8k_ostherap.htm |